𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dyadic International reports 2010 financial results


Publisher
Elsevier Science
Year
2011
Weight
49 KB
Volume
2011
Category
Article
ISSN
1351-4180

No coin nor oath required. For personal study only.

✦ Synopsis


At the Annual General Meeting of Clariant AG, held on 31 Mar 2011, the way was cleared for takeover of more than 95% of the shares in SΓΌd-Chemie AG. Clariant's shareholders voted in favour of a capital increase, which is a basic requirement for takeover of the SΓΌd-Chemie shares by Clariant. Part of the transaction is to be realised in the form of a share swap with SΓΌd-Chemie's long-standing share-holders.


πŸ“œ SIMILAR VOLUMES


Dyadic International reports 1Q 2011 fin
πŸ“‚ Article πŸ“… 2011 πŸ› Elsevier Science βš– 54 KB

The Managing Board and the Supervisory Board of SΓΌd-Chemie AG have published their joint statement on the takeover offer made to SΓΌd-Chemie AG shareholders by Clariant Verwaltungsgesellschaft mbH and on the offer document published on 17 May 2011. Applying various valuation methods, the Managing Boa

Verenium reports financial results for 3
πŸ“‚ Article πŸ“… 2011 πŸ› Elsevier Science βš– 60 KB

improve manufacturing processes and develop new technologies," he added. Al-Ubaid also noted that research excellence had played a large part in making SABIC an outstanding petrochemical success story, and stated that by continuing to invest in technology, SABIC is driving the petrochemical industry

Verenium reports financial results for t
πŸ“‚ Article πŸ“… 2010 πŸ› Elsevier Science βš– 52 KB

## Umicore 1H 2010 For its 1H 2010, Umicore has reported revenues of €987.1 M (€860.2 M for its 1H 2009), recurring EBIT of €186.3 M (€49.5 M), EBITDA of €244.3 M (€111.6 M), basic EPS of €1.24 (€0.18), R&D expenditure of €66.2 M (6% of revenues), and capital expenditure of €75.5 M. An interim div

Grace reports 2Q financial results
πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science βš– 31 KB

## Chiral intermediates plants for BASF BASF is operating three plants for making chiral intermediates to meet rising demand from life science customers. The new plants reflect the advancement in the firm's proprietary technology and provide solutions to the limitations of previous plants in use.